Azra Idrizovic, DO
Ophthalmology · Dallas, TXNPI 1487905634
Payments from drug & device makers
Across 242 payments — averaging $117.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$12K
- Sight Sciences, Inc.$7K
- Alcon$5K
- AbbVie$3K
- Glaukos Corporation$778
- Sun Pharmaceutical Industries Inc.$185
- plus $872 from 10 others
What the payments were for
- Consulting fees$5002%
- Speaking & faculty fees$20,05471%
- Food & beverage$7,77227%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 28 | $11,710 |
| Sight Sciences, Inc. | 26 | $7,139 |
| Alcon | 39 | $4,922 |
| AbbVie(2 entities) | 112 | $2,720 |
| Glaukos Corporation | 9 | $778 |
| Sun Pharmaceutical Industries Inc. | 3 | $185 |
| Bausch & Lomb Americas Inc. | 8 | $164 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $153 |
| Amgen | 1 | $141 |
| Ivantis, Inc | 1 | $129 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $115 |
| Novartis | 3 | $66 |
| Kala Pharmaceuticals, Inc. | 2 | $41 |
| NEW World Medical,inc. | 2 | $25 |
| Thea Pharma Inc. | 1 | $20 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$15,047
- Rhopressa$14,922
- OMNI(R) SURGICAL SYSTEM (US)$6,798
- SION SURGICAL INSTRUMENT$6,145
- XEN GLAUCOMA TREATMENT SYSTEM$575
- AcrySof IQ PanOptix$180
- iStent Trabecular Micro-Bypass System Model iS3$163
- Tecnis IOL$153
- TEPEZZA$141
- AcrySof IQ PanOptix UV IOL$136
- AcrySof IQ VIVITY$136
- Hydrus$129
- CEQUA$125
- PanOptix$125
- Clareon$122
- iStent inject W$120
- IACCESS$120
- XEN$109
How this compares
$28,326 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 281 | $113,438 |
| RocklatanNetarsudil Mesylat/Latanoprost | 78 | $42,398 |
| CombiganBrimonidine Tartrate/Timolol | 75 | $32,799 |
| RhopressaNetarsudil Mesylate | 69 | $30,135 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 152 | $27,045 |
| XiidraLifitegrast | 25 | $23,454 |
| RestasisCyclosporine | 22 | $22,161 |
| VyzultaLatanoprostene Bunod | 53 | $21,841 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 85 | $19,315 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,185 | $16,345 |
| Prednisolone Acetate | 410 | $16,197 |
| Latanoprost | 1,383 | $10,673 |
| Alphagan PBrimonidine Tartrate | 29 | $10,134 |
| Travoprost | 96 | $10,074 |
| Brimonidine Tartrate | 742 | $9,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $2,720 | $178,531407 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $11,710 | $72,534147 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $164 | $45,29578 claims |
| AlconSimbrinza | $4,922 | $19,31585 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $115 | $5,60051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Dallas
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Jeffrey WhitmanDallas$1.7M
- Oluwatosin SmithDallas$1.7M
- Davinder GroverDallas$1.3M
- Robert WangDallas$594K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.